Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.

Literature DB >> 23997982

Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.

Melda Comert¹, Yusuf Baran, Guray Saydam.

Abstract

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by a reciprocal translocation between long arms of chromosomes 9 and 22 t(9;22) that generates the BCR-ABL fusion gene. If left untreated, newly diagnosed chronic phase CML patients finally progress to accelerated and blastic phase. After the introduction of tyrosine kinase inhibitors (TKIs), treatment strategies of CML changed dramatically. However, the development of resistance to TKIs started to create problems over time. In this review, the current information about CML biology before and after imatinib mesylate treatment is summarized.

Entities: Chemical Disease Gene Species

Keywords: Chronic myeloid leukemia; imatinib mesylate; moleculer biology

Year: 2013 PMID： 23997982 PMCID： PMC3755521

Source DB: PubMed Journal: Am J Blood Res ISSN： 2160-1992

57 in total

1. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

Authors: X Sun; J E Layton; A Elefanty; G J Lieschke
Journal: Blood Date: 2001-04-01 Impact factor: 22.113

2. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.

Authors: J R Engler; A Frede; V A Saunders; A C W Zannettino; T P Hughes; D L White
Journal: Leukemia Date: 2010-02-11 Impact factor: 11.528

3. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors: Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Gianantonio Rosti; Fausto Castagnetti; Angela Poerio; Ilaria Iacobucci; Marilina Amabile; Elisabetta Abruzzese; Ester Orlandi; Franca Radaelli; Fabrizio Ciccone; Mario Tiribelli; Roberto di Lorenzo; Clementina Caracciolo; Barbara Izzo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; Giovanni Martinelli
Journal: Clin Cancer Res Date: 2006-12-15 Impact factor: 12.531

Review 4. New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.

Authors: A Stefanachi; F Leonetti; O Nicolotti; M Catto; L Pisani; S Cellamare; C Altomare; A Carotti
Journal: Curr Cancer Drug Targets Date: 2012-06 Impact factor: 3.428

5. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Authors: Amie S Corbin; Anupriya Agarwal; Marc Loriaux; Jorge Cortes; Michael W Deininger; Brian J Druker
Journal: J Clin Invest Date: 2010-12-13 Impact factor: 14.808

6. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Authors: Stephanie G Willis; Thoralf Lange; Shadmehr Demehri; Sandra Otto; Lucy Crossman; Dietger Niederwieser; Eric P Stoffregen; Shannon McWeeney; Ines Kovacs; Byung Park; Brian J Druker; Michael W Deininger
Journal: Blood Date: 2005-05-24 Impact factor: 22.113

Review 7. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.

Authors: Dale Bixby; Moshe Talpaz
Journal: Hematology Am Soc Hematol Educ Program Date: 2009

5. The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML).

Authors: Željka Tkalčić Švabek; Marina Josipović; Ivana Horvat; Renata Zadro; Sanja Davidović-Mrsić
Journal: Blood Res Date: 2018-06-25

5 in total

Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.

1. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

2. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.

3. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Review 4. New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.

5. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

6. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Review 7. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.

Review 8. Characterization of cancer stem cells in chronic myeloid leukaemia.

Review 9. Imatinib: a targeted clinical drug development.

Review 10. Targeted chronic myeloid leukemia therapy: Seeking a cure.

Review 1. Targeting cancer with kinase inhibitors.

2. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.

Review 3. MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia.

Review 4. Targeting phosphatases of regenerating liver (PRLs) in cancer.

5. The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML).